CONFERENCE SERIES: Clinical Trials & Translational Medicine 

Recorded at: PEGS: The Essential Protein Engineering Summit: 

Digital Course:Translational Strategies for Development of Monoclonal Antibodies From Discovery to Clinic 

 


Order DVD2011 SC2 DVD Cover About this Product: 

The effective information flow and translation of accumulated knowledge across various antibody development stages remains a major challenge. Successful strategies for development of monoclonal antibodies require integration of relevant knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, pharmacokinetic (PK)-pharmacodynamic (PD) properties, and antibody cross-reactivity across species from the early stages of antibody development. Biophysical measurements are one of the critical components necessary for the design of effective translational strategies for lead selection and evaluation of the relevant animal species for preclinical safety and efficacy studies. Incorporation of effective translational strategies from the early stages of the antibody development process is a necessity; when considered it not only reduces development time and cost, but also fosters implementation of rational decision making throughout all phases of antibody development.  

Preview: 

 

About this Product: 

6 Presentations
258 Slides
Over 316 Minutes
Individual: $345Site License: $1380

 

 

 

Agenda At A Glance: 

Translational Considerations For Development Of Monoclonal Antibodies: Focus On Early Discovery 

Considerations for Target Selection, Antibody Screening and mAb Preclinical DevelopmentGadi Bornstein  
Gadi Bornstein, Ph.D., Principal Scientist, AstraZeneca R&D  

Biographies: Dr. Bornstein has experience in research and development with an emphasis in development of biologics and monoclonal antibodies. Dr. Bornstein is a Principal Scientist at AstraZeneca, where he currently leads several antibody programs within the Preclinical oncology portfolio. Dr. Bornstein is author or co-author of more than 25 scientific publications, abstracts, and patents.

Antibody Affinity and Biophysical Characterization: Biacore, Kinexa, and FACSScott Klakamp  
Scott Klakamp, Ph.D., Research Fellow, Biophysical Chemistry and Research Informatics, Takeda San Francisco  

Biography: Dr. Scott Klakamp is a Research Fellow at Takeda San Francisco. He leads the Biophysical Chemistry and Research Informatics Groups and has extensive experience in research and development involving the biophysical and analytical characterization of biologics and monoclonal antibodies. Dr. Klakamp is one of the leading scientists in utilizing Biacore®, KinExA®, and FACS techniques to measure the binding kinetics and equilibrium constants of human monoclonal antibody/antigen complexes.


Preclinical Considerations-A science Based Approach: Design Goal, MOA, Choice of species, and Preclinical plans
 

Mohammad Tabrizi Mohammad Tabrizi, Ph.D., Sr. Fellow, Head PK/PD, Merck Research Laboratory, MRL-Palo Alto 

Biography: Mohammad Tabrizi PhD is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies.


End of Part 1 

Translational Considerations For Development Of Monoclonal Antibodies: Focus On Nonclinical Development To Clinic 

Considerations for Immunoassay Development in Support of Pharmacokinetic, Immunogenicity & Biomarker EvaluationCherryl Funelas  
Cherryl Funelas, Manager, Bioanalytical Development, Takeda San Francisco  

Biography: Cherryl Funelas is a Manager of Bioanalytical Development in Takeda San Francisco.  She has extensive experience in Immunoassays, and Bioanalytical Sciences.  Her area of expertise spans from supporting preclinical and clinical studies and has developed numerous pharmacokinetic (PK), immunogenicity (IM), and biomarker assays.  She was responsible in establishing GLP compliant laboratories at Abgenix, Inc in Fremont, CA (acquired by Amgen) and AstraZeneca/Medimmune, Hayward, CA.


Antibody Safety, Species Selection, Introduction to Surrogate Approaches in Development of Monoclonal Antibodies

Mohammad Tabrizi, Ph.D., Sr. Fellow, Head PK/PD, Merck Research Laboratory, MRL-Palo Alto
 

Translation of exposure-response data from discovery into the clinic in support of FIH dosing
Mohammad Tabrizi, Ph.D., Sr. Fellow, Head PK/PD, Merck Research Laboratory, MRL-Palo Alto
 

End of Part 2 

About the Conference: 

PEGS is the essential antibody and protein engineering event of the year, where what you learn can be directly applied to your work. The event provides 1,200+ participants to network with their peers and learn about unpublished science in the session rooms. Delegates engage in problem solving breakout discussions and gain insight from over 60 exhibitors, and view the 155 posters in the exhibit hall.